359 related articles for article (PubMed ID: 20560994)
21. Apathy in Alzheimer's disease and frontotemporal dementia: Distinct clinical profiles and neural correlates.
Kumfor F; Zhen A; Hodges JR; Piguet O; Irish M
Cortex; 2018 Jun; 103():350-359. PubMed ID: 29704671
[TBL] [Abstract][Full Text] [Related]
22. Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
Rea R; Carotenuto A; Traini E; Fasanaro AM; Manzo V; Amenta F
J Alzheimers Dis; 2015; 48(2):377-83. PubMed ID: 26402001
[TBL] [Abstract][Full Text] [Related]
23. Brain Regions Involved in Arousal and Reward Processing are Associated with Apathy in Alzheimer's Disease and Frontotemporal Dementia.
Huey ED; Lee S; Cheran G; Grafman J; Devanand DP;
J Alzheimers Dis; 2017; 55(2):551-558. PubMed ID: 27802220
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological treatment of non-cognitive disturbances in dementia disorders.
Parnetti L; Amici S; Lanari A; Gallai V
Mech Ageing Dev; 2001 Nov; 122(16):2063-9. PubMed ID: 11589923
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological treatment of apathy in Lewy body disorders: A systematic review.
Liu J; Cooper CA; Weintraub D; Dahodwala N
Parkinsonism Relat Disord; 2019 Mar; 60():14-24. PubMed ID: 30470658
[TBL] [Abstract][Full Text] [Related]
26. Prevalence, treatment, and neural correlates of apathy in different forms of dementia: a narrative review.
Parrotta I; Cacciatore S; D'Andrea F; D'Anna M; Giancaterino G; Lazzaro G; Arcara G; Manzo N
Neurol Sci; 2024 Apr; 45(4):1343-1376. PubMed ID: 38015288
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Cumbo E; Ligori LD
J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
[TBL] [Abstract][Full Text] [Related]
28. Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease.
Nobili A; Latagliata EC; Viscomi MT; Cavallucci V; Cutuli D; Giacovazzo G; Krashia P; Rizzo FR; Marino R; Federici M; De Bartolo P; Aversa D; Dell'Acqua MC; Cordella A; Sancandi M; Keller F; Petrosini L; Puglisi-Allegra S; Mercuri NB; Coccurello R; Berretta N; D'Amelio M
Nat Commun; 2017 Apr; 8():14727. PubMed ID: 28367951
[TBL] [Abstract][Full Text] [Related]
29. Serotonergic system, cognition, and BPSD in Alzheimer's disease.
Chakraborty S; Lennon JC; Malkaram SA; Zeng Y; Fisher DW; Dong H
Neurosci Lett; 2019 Jun; 704():36-44. PubMed ID: 30946928
[TBL] [Abstract][Full Text] [Related]
30. Apathy as a feature of prodromal Alzheimer's disease: an FDG-PET ADNI study.
Delrieu J; Desmidt T; Camus V; Sourdet S; Boutoleau-Bretonnière C; Mullin E; Vellas B; Payoux P; Lebouvier T;
Int J Geriatr Psychiatry; 2015 May; 30(5):470-7. PubMed ID: 24953008
[TBL] [Abstract][Full Text] [Related]
31. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.
Finkel SI
Clin Ther; 2004 Jul; 26(7):980-90. PubMed ID: 15336465
[TBL] [Abstract][Full Text] [Related]
32. Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies.
Breitve MH; Brønnick K; Chwiszczuk LJ; Hynninen MJ; Aarsland D; Rongve A
Alzheimers Res Ther; 2018 Aug; 10(1):83. PubMed ID: 30121084
[TBL] [Abstract][Full Text] [Related]
33. The role of dopamine in the pathophysiology and treatment of apathy.
Chong TT; Husain M
Prog Brain Res; 2016; 229():389-426. PubMed ID: 27926449
[TBL] [Abstract][Full Text] [Related]
34. Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
Oka M; Nakaaki S; Negi A; Miyata J; Nakagawa A; Hirono N; Mimura M
Psychogeriatrics; 2016 Mar; 16(2):121-34. PubMed ID: 26114924
[TBL] [Abstract][Full Text] [Related]
35. Treating apathy in Alzheimer's disease.
Boyle PA; Malloy PF
Dement Geriatr Cogn Disord; 2004; 17(1-2):91-9. PubMed ID: 14564128
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease.
Popp J; Arlt S
Curr Opin Psychiatry; 2011 Nov; 24(6):556-61. PubMed ID: 21934621
[TBL] [Abstract][Full Text] [Related]
37. Improvement of neuronal integrity with methylphenidate treatment for apathy in Alzheimer's disease.
Padala PR; Padala KP; Samant RS; James GA
Int Psychogeriatr; 2020 Apr; 32(4):539-540. PubMed ID: 32019622
[No Abstract] [Full Text] [Related]
38. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease.
Waldemar G; Gauthier S; Jones R; Wilkinson D; Cummings J; Lopez O; Zhang R; Xu Y; Sun Y; Knox S; Richardson S; Mackell J
Int J Geriatr Psychiatry; 2011 Feb; 26(2):150-7. PubMed ID: 20597141
[TBL] [Abstract][Full Text] [Related]
39. New pharmacological options for treating advanced Parkinson's disease.
Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
[TBL] [Abstract][Full Text] [Related]
40. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
